We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+9.22%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$10.2B
AUM Growth
-$9.59M
Cap. Flow
-$234M
Cap. Flow %
-2.3%
Top 10 Hldgs %
76.44%
Holding
39
New
5
Increased
9
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$212M
2
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$97.2M
3
TERN
Terns Pharmaceuticals
TERN
+$55.2M
4
CELC icon
Celcuity
CELC
+$28.8M
5
AVTX icon
Avalo Therapeutics
AVTX
+$22M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$393M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$256M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$79.9M
4
PTCT icon
PTC Therapeutics
PTCT
+$52M
5
ORKA
Oruka Therapeutics
ORKA
+$40.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%

No holdings matched the selected filter criteria.

1 2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Avoro Capital Advisors held 39 positions worth $10.2B, down 0.09% from $10.2B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Avoro Capital Advisors's Q1 2026 filing shows 5 new, 9 increased, 7 reduced and 7 closed positions. Its largest new stake was Cytokinetics: 3,333,333 shares worth $220M. The largest sale was Avidity Biosciences, an estimated $393M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

  • Avoro Capital Advisors's largest Q1 2026 buy was Cytokinetics: 3,333,333 shares worth $220M.
  • Avoro Capital Advisors added most to Terns Pharmaceuticals in Q1 2026, an estimated $55.2M increase.
  • Avoro Capital Advisors's biggest Q1 2026 reduction was Centessa Pharmaceuticals, cutting an estimated $79.9M.
  • Avoro Capital Advisors fully exited Avidity Biosciences in Q1 2026, selling an estimated $393M.
  • Avoro Capital Advisors's ten largest holdings make up 76% of its $10.2B portfolio in Q1 2026.
  • Avoro Capital Advisors opened 5 new positions and closed 7 in Q1 2026.
  • Avoro Capital Advisors's portfolio value fell 0.09% quarter-over-quarter to $10.2B.

Based on Avoro Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.